Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 11/20 | 0.49 |
| ▸ | PIM1 | P11309 | 2/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.45 |
| ▸ | IKBKB | O14920 | 2/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3324379 | 1.00 | IRAK4 (0.49) | IRAK4PIM1PIM2IKBKBCHUK | |
| SCHEMBL3325033 | 0.88 | CHRNB4 (0.45) | IRAK4PIM1PIM2IKBKBCHUK | |
| SCHEMBL3325029 | 0.88 | CHRNB4 (0.45) | IRAK4PIM1PIM2IKBKBCHUK | |
| SCHEMBL3325170 | 0.87 | IRAK4 (0.53) | IRAK4PIM1PIM2IKBKBCHUK | |
| SCHEMBL3324261 | 0.87 | IRAK4 (0.53) | IRAK4PIM1PIM2IKBKBCHUK | |
| SCHEMBL3324549 | 0.87 | IKBKB (0.46) | IRAK4PIM1PIM2IKBKBCHUK | |
| SCHEMBL3324556 | 0.87 | IKBKB (0.46) | IRAK4PIM1PIM2IKBKBCHUK | |
| SCHEMBL3320736 | 0.85 | IKBKB (0.45) | IRAK4PIM1PIM2IKBKBCHUK | |
| SCHEMBL3326074 | 0.85 | IKBKB (0.45) | IRAK4PIM1PIM2IKBKBCHUK | |
| SCHEMBL3321236 | 0.85 | IKBKB (0.51) | IRAK4PIM1PIM2IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120858-A1 | Piperidine Derivatives | PFIZER INC. | 2010-05-13 | — | — | US | disclosed |
| EP-2066630-A1 | PIPERIDINE DERIVATIVES | Pfizer Products Incorporated (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008023258-A1 | PIPERIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120858-A1 | Piperidine Derivatives | P2RX5, P2RX7, P2RX1 | IRAK4 1593/4885PIM1 3450/4885PIM2 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.